News and Events, Recent News

BriaCell Provides Highlights of Scientific and Clinical Findings at AACR

– Early data points to safety and early efficacy of Bria-IMT™ in Advanced Stage IV Breast cancer – BERKELEY, Calif. and VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that it has presented […]

News and Events, Recent Events

Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, is Featured in an Exclusive New Audio Interview with SmallCapVoice.com

AUSTIN, Texas—3/9/18– SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. (“BriaCell”) (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. Williams, is featured in a new audio interview at SmallCapVoice.com, Inc. The interview outlining Bricell’s current news and efforts can be heard at https://smallcapvoice.com/blog/4-11-18-smallcapvoice-interview-with-briacell-therapeutics-corp-bctxf/. […]

News and Events, Recent News

BriaCell to Present Encouraging Clinical Data at AACR 2018

– Early Evidence of Safety and Impressive Anti-Tumor Activity of Bria-IMT™- BERKELEY, Calif. and VANCOUVER, British Columbia, April 10, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it has been selected to present a late-breaking poster presentation at the […]

News and Events, Recent News

BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal

BERKELEY, Calif. and VANCOUVER, British Columbia, April 3, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the acceptance of a manuscript describing the novel mechanism of action of the Company’s lead product candidate, Bria-IMT™. The findings detailed in […]